Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: A role for apolipoprotein E?

Diabetes

Volumn 55, Issue 5, 2006, Pages 1491-1496

  Dallinga Thie, Geesje M ^a,e   Van Tol, Arie ^a,b   Hattori, Hiroaki ^c   Rensen, Patrick C N ^d   Sijbrands, Eric J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Kawagoe shi   (Japan)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NONE   (Netherlands)

Author keywords

Apo, apolipoprotein; DALI, Diabetes Atorvastatin Lipid Intervention; PLTP, phospholipid transfer protein

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIPOLYSIS; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; DRUG EFFECT; GENETICS; GENOTYPE; MIDDLE AGED; MULTICENTER STUDY;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEINS E; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; PLACEBOS; PYRROLES;

EID: 33745323890     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-1685     Document Type: Article

References (46)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
2. Reaven GM: The insulin resistance syndrome. Curr Atheroscler Rep 5:364-371, 2003
3. Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82:495-506, 1990
4. Barter P: HDL: a recipe for longevity. Atheroscler Suppl 5:25-31, 2004
5. Stein O, Stein Y: Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 178:217-230, 2005
6. Albers JJ, Cheung MC: Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. Curr Opin Lipidol 15:255-260, 2004
7. Rye KA, Barter PJ: Changes in the size and density of human high-density lipoproteins promoted by a plasmaconversion factor. Biochim Biophys Acta 875:429-438, 1986
8. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, vanTol A, Ehnholm C: Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268:4032-4036, 1993
9. Van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, Ehnholm S, Grosveld F, van der Kamp A, de Crom R: Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082-1088, 2000
10. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 103:907-914, 1999
11. Van Tol A: Phospholipid transfer protein. Curr Opin Lipidol 13:135-139, 2002
12. Qin SC, Kawano K, Bruce C, Lin M, Bisgaier C, Tall AR, Jiang XC: Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J Lipid Res 41:269-276, 2000
13. Jiang XC, Li Z, Liu R, Yang XP, Pan M, Lagrost L, Fisher EA, Williams KJ: Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem 280:18336-18340, 2005
14. Jiang XC, Qin SC, Qiao CP, Kawano K, Lin M, Skold A, Xiao X, Tall AR: Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7:849-854, 2001
15. Van Haperen R, van Tol A, van Gent T, Scheek L, Visser P, van der Kamp A, Grosveld F, de Crom R: Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 277:48938-48943, 2002
16. Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Sadeghi-Niaraki F, van Tol A: Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J Lipid Res 45:805-811, 2004
17. Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, Schneider M, Lagrost L, Xiao X, Jiang XC: Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23:1601-1607, 2003
18. Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, Jiang XC: High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 23:1857-1862, 2003
19. Riemens SC, van Tol A, Sluiter WJ, Dullaart RP: Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 41:929-934, 1998
20. Colhoun HM, Taskinen MR, Otvos JD, van den Berg P, O'Connor J, van Tol A: Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 51:3300-3305, 2002
21. Jonkers IJ, Smelt AH, Hattori H, Scheek LM, van Gent T, de Man FH, Van der Laarse A, van Tol A: Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res 44:1462-1469, 2003
22. Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, van Tol A: Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188-194, 1994
23. Kaser S, Sandhofer A, Foger B, Ebenbichler CF, Igelseder B, Malaimare L, Paulweber B, Patsch JR: Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 44:1111-1117, 2001
24. Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G: ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 42:281-290, 2001
25. Vuletic S, Jin LW, Marcovina SM, Peskind ER, Moller T, Albers JJ: Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. J Lipid Res 44:1113-1123, 2003
26. Vuletic S, Peskind ER, Marcovina SM, Quinn JF, Cheung MC, Kennedy H, Kaye JA, Jin LW, Albers JJ: Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res 80:406-413, 2005
27. Desrumaux C, Risold PY, Schroeder H, Deckert V, Masson D, Athias A, Laplanche H, Le GN, Blache D, Jiang XC, Tall AR, Desor D, Lagrost L: Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice. FASEB J 19:296-297, 2005
28. Gander R, Eller P, Kaser S, Theurl I, Walter D, Sauper T, Ritsch A, Patsch JR, Foger B: Molecular characterization of rabbit phospholipid transfer protein: choroid plexus and ependyma synthesize high levels of phospholipid transfer protein. J Lipid Res 43:636-645, 2002
29. Oka T, Kujiraoka T, Ito M, Nagano M, Ishihara M, Iwasaki T, Egashira T, Miller NE, Hattori H: Measurement of human plasma phospholipid transfer protein by sandwich ELISA. Clin Chem 46:1357-1364, 2000
30. Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, Miller NE, Metso J, Olkkonen VM, Ehnholm C, Jauhiainen M, Hattori H: Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res 41:1651-1657, 2000
31. Murdoch SJ, Wolfbauer G, Kennedy H, Marcovina SM, Carr MC, Albers JJ: Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J Lipid Res 43:281-289, 2002
32. Karkkainen M, Oka T, Olkkonen VM, Metso J, Hattori H, Jauhiainen M, Ehnholm C: Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem 277:15413-15418, 2002
33. Siggins S, Karkkainen M, Tenhunen J, Metso J, Tahvanainen E, Olkkonen VM, Jauhiainen M, Ehnholm C: Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA. J Lipid Res 45:387-395, 2004
34. Janis MT, Metso J, Lankinen H, Strandin T, Olkkonen VM, Rye KA, Jauhiainen M, Ehnholm C: Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 331:333-340, 2005
35. Diabetes Atorvastin Lipid Intervention (DALI) Study Group: The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebocontrolled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335-1341, 2001
36. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 23:S4-S19, 2000
37. Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. Clin Chem 18:499-502, 1972
38. Speijer H, Groener JE, van Ramshorst E, van Tol A: Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90:159-168, 1991
39. Damen J, Regts J, Scherphof G: Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins: dependence on cholesterol content and phospholipid composition. Biochim Biophys Acta 665:538-545, 1981
40. Schneider M, Verges B, Klein A, Miller ER, Deckert V, Desrumaux C, Masson D, Gambert P, Brun JM, Fruchart-Najib J, Blache D, Witztum JL, Lagrost L: Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 53:2633-2639, 2004
41. Cheung MC, Knopp RH, Retzlaff B, Kennedy H, Wolfbauer G, Albers JJ: Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity. Biochim Biophys Acta 1587:53-59, 2002
42. Poirier P, Lemieux I, Mauriege P, Dewailly E, Blanchet C, Bergeron J, Despres JP: Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension 45:363-367, 2005
43. Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Lankhuizen I, van Tol A: Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res 43:1875-1880, 2002
44. Huuskonen J, Ekström M, Tahvanainen E, Vainio A, Metso J, Pussinen P, Ehnholm C, Olkkonen VM, Jauhiainen M: Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis 151:451-461, 2000
45. Oka T, Yamashita S, Kujiraoka T, Ito M, Nagano M, Sagehashi Y, Egashira T, Nanjee MN, Hirano K, Miller NE, Matsuzawa Y, Hattori H: Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia. J Lipid Res 43:1236-1243, 2002
46. Siggins S, Jauhiainen M, Olkkonen VM, Tenhunen J, Ehnholm C: PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. J Lipid Res 44:1698-1704, 2003